Grifols has been granted a patent for methods and compositions that utilize blood plasma and its fractions to treat aging-related diseases, enhance muscle recovery, and prevent muscle degeneration. The patent specifically claims a method using Plasma Fraction IV-1 to improve muscle regeneration in affected subjects. GlobalData’s report on Grifols gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Grifols, Attenuated virus-based vaccines was a key innovation area identified from patents. Grifols's grant share as of July 2024 was 52%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of muscle degeneration using blood plasma fractions
The granted patent US12059453B2 outlines a method aimed at enhancing muscle regeneration to alleviate symptoms associated with various muscle disorders characterized by muscle degeneration. Central to this method is the administration of a specific Plasma Fraction, identified as plasma fraction IV-1 paste suspension, in an effective amount to promote muscle recovery. The claims detail that this method can be applied to subjects diagnosed with muscle disorders resulting from acute injuries, dystrophies, or other conditions such as muscle atrophy and weakness. Notably, the patent specifies that the method can be tailored to address specific types of dystrophies, including Duchenne and Becker muscular dystrophy, among others.
Additionally, the patent describes the use of a Pulse Dose dosing regimen for administering the Plasma Fraction, which may enhance the effectiveness of the treatment. The claims further encompass a broad range of muscle disorders, including those resulting from sports-related injuries and various neuromuscular conditions. The method not only aims to improve muscle regeneration but also focuses on reducing or potentially eliminating the symptoms associated with these disorders, thereby offering a therapeutic approach for individuals suffering from muscle degeneration.
To know more about GlobalData’s detailed insights on Grifols, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
